His clinical interests include brain tumors, osteosarcoma, precision oncology, and genomics and genetics of cancer.

He’s accelerating the pace and success rate of clinical trials in pediatric cancer patients using new genomic technologies to better understand pediatric brain and bone cancers and rapidly develop new therapeutic treatments for patients via translational research, especially difficult to treat brain tumors.

By combining in silico drug screening and mouse model findings with genomic medicine to choose the best therapy for each patient, Lau hopes to improve the speed and outcome of clinical trials and reduce cancer care side effects for children. His latest research is gaining insight on the underlying genomics of common and difficult to treat brain tumor to target them genetically with novel therapeutics. Plus, he’s working to test and reposition current heart drugs to help expand the fight against complicated brain tumors. More recently he is leading an international team of investigators in industry and academia to develop a cloud-based platform to facilitate data sharing and integration through global collaboration.